Drug Development Pharma - August 23, 2016
AZ, Lilly receive fast track designation
AstraZeneca and Eli Lilly and Company have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the development and review of new […]
Clinical Trials - April 13, 2016
AZ, Eli Lilly continue with AMARANTH clinical trial
AstraZeneca and Eli Lilly and Company announces that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial. The AMARANTH independent data monitoring committee recommended the study continue […]
Profiles in Business - April 21, 2014
Jan Lundberg: The long view of R&D at Eli Lilly
Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]
